T0	KEYPHRASE-NOTYPES 0 12	Lyme disease
T1	KEYPHRASE-NOTYPES 69 78	incidence
T2	KEYPHRASE-NOTYPES 82 88	Canada
T3	KEYPHRASE-NOTYPES 119 129	high index
T4	KEYPHRASE-NOTYPES 133 142	suspicion
T5	KEYPHRASE-NOTYPES 144 164	Laboratory diagnosis
T6	KEYPHRASE-NOTYPES 170 184	2-step process
T7	KEYPHRASE-NOTYPES 195 199	case
T8	KEYPHRASE-NOTYPES 205 224	emergency physician
T9	KEYPHRASE-NOTYPES 237 252	screening ELISA
T10	KEYPHRASE-NOTYPES 254 287	enzyme-linked immunosorbent assay
T11	KEYPHRASE-NOTYPES 298 305	patient
T12	KEYPHRASE-NOTYPES 314 326	ELISA result
T13	KEYPHRASE-NOTYPES 361 373	Western blot
T14	KEYPHRASE-NOTYPES 377 398	positive Western blot
T15	KEYPHRASE-NOTYPES 419 428	diagnosis
T16	KEYPHRASE-NOTYPES 431 443	Lyme disease
T17	KEYPHRASE-NOTYPES 472 479	patient
T18	KEYPHRASE-NOTYPES 487 496	new onset
T19	KEYPHRASE-NOTYPES 500 510	Bell palsy
T20	KEYPHRASE-NOTYPES 512 545	Current treatment recommendations
T21	KEYPHRASE-NOTYPES 569 581	Lyme disease
T22	KEYPHRASE-NOTYPES 587 621	central nervous system involvement
T23	KEYPHRASE-NOTYPES 630 641	ceftriaxone
T24	KEYPHRASE-NOTYPES 646 656	oxycycline
T25	KEYPHRASE-NOTYPES 671 678	patient
T26	KEYPHRASE-NOTYPES 692 704	Western blot
T27	KEYPHRASE-NOTYPES 717 729	prescription
T28	KEYPHRASE-NOTYPES 733 744	doxycycline
T29	KEYPHRASE-NOTYPES 759 777	full 21-day course
T30	KEYPHRASE-NOTYPES 787 796	follow-up
T31	KEYPHRASE-NOTYPES 825 852	Lyme disease facial palsies
